Nokia (NOK) EPS Estimated At $0.11; Last Week Incyte (INCY) Analysts

January 14, 2018 - By Adrian Mccoy

Analysts expect Nokia Corporation (NYSE:NOK) to report $0.11 EPS on February, 1.They anticipate $0.02 EPS change or 15.38% from last quarter’s $0.13 EPS. NOK’s profit would be $602.56M giving it 11.07 P/E if the $0.11 EPS is correct. After having $0.11 EPS previously, Nokia Corporation’s analysts see 0.00% EPS growth. The stock increased 1.04% or $0.05 during the last trading session, reaching $4.87. About 7.05 million shares traded. Nokia Corporation (NYSE:NOK) has risen 19.54% since January 14, 2017 and is uptrending. It has outperformed by 2.84% the S&P500.

Among 24 analysts covering Incyte (NASDAQ:INCY), 20 have Buy rating, 0 Sell and 4 Hold. Therefore 83% are positive. Incyte had 75 analyst reports since August 6, 2015 according to SRatingsIntel. On Thursday, October 12 the stock rating was maintained by BMO Capital Markets with “Buy”. BMO Capital Markets maintained the shares of INCY in report on Tuesday, January 2 with “Buy” rating. Zacks downgraded the stock to “Buy” rating in Wednesday, August 12 report. On Tuesday, August 18 the stock rating was maintained by Argus Research with “Buy”. The firm has “Outperform” rating given on Wednesday, October 12 by RBC Capital Markets. The stock has “Overweight” rating by Barclays Capital on Wednesday, August 10. The firm earned “Hold” rating on Tuesday, November 21 by RBC Capital Markets. The stock of Incyte Corporation (NASDAQ:INCY) has “Buy” rating given on Wednesday, November 4 by UBS. The stock of Incyte Corporation (NASDAQ:INCY) earned “Overweight” rating by Barclays Capital on Wednesday, August 2. The company was maintained on Wednesday, November 1 by BMO Capital Markets. See Incyte Corporation (NASDAQ:INCY) latest ratings:

02/01/2018 Broker: BMO Capital Markets Rating: Buy New Target: $172.0 Maintain
02/01/2018 Broker: RBC Capital Markets Old Rating: Sector Perform New Rating: Outperform Old Target: $136 Upgrade
13/12/2017 Broker: Deutsche Bank Rating: Hold New Target: $106 Initiates Coverage On
21/11/2017 Broker: RBC Capital Markets Rating: Hold New Target: $120.0 Maintain
31/10/2017 Broker: SunTrust Rating: Buy New Target: $155.0 Maintain
01/11/2017 Broker: BMO Capital Markets Rating: Outperform Old Target: $162 New Target: $166 Maintain
26/10/2017 Broker: BMO Capital Markets Rating: Outperform Old Target: $163 New Target: $163 Maintain
12/10/2017 Broker: BMO Capital Markets Rating: Buy New Target: $163.0 Maintain
06/10/2017 Broker: Goldman Sachs Rating: Buy New Target: $160.0
04/10/2017 Broker: Jefferies Rating: Buy New Target: $148.0 Maintain

Nokia Corporation, together with its subsidiaries, provides network infrastructure and related services worldwide. The company has market cap of $26.68 billion. The firm operates through three divisions: Ultra Broadband Networks, IP Networks and Applications, and Nokia Technologies. It currently has negative earnings. It offers mobile networking solutions, such as hardware, software, and services for telecommunications operators, enterprises, and related markets/verticals; radio access network solutions; Internet protocol multimedia subsystem/voice over LTE, subscriber data management and other virtualized software infrastructure solutions; backhaul solutions; and network planning, implementation, operations, and maintenance solutions.

Among 24 analysts covering Nokia (NYSE:NOK), 10 have Buy rating, 3 Sell and 11 Hold. Therefore 42% are positive. Nokia had 47 analyst reports since August 26, 2015 according to SRatingsIntel. CLSA downgraded Nokia Corporation (NYSE:NOK) on Friday, October 28 to “Underperform” rating. Morgan Stanley upgraded Nokia Corporation (NYSE:NOK) on Tuesday, February 7 to “Overweight” rating. The stock has “Outperform” rating by CLSA on Wednesday, May 25. The firm earned “Buy” rating on Friday, January 15 by Argus Research. On Thursday, September 3 the stock rating was maintained by Bernstein with “Outperform”. The firm earned “Hold” rating on Friday, April 28 by BMO Capital Markets. The company was downgraded on Tuesday, November 15 by Bank of America. On Thursday, July 27 the stock rating was maintained by Canaccord Genuity with “Hold”. As per Wednesday, November 16, the company rating was downgraded by BMO Capital Markets. On Friday, January 13 the stock rating was upgraded by Natixis to “Buy”.

Investors sentiment increased to 1.04 in 2017 Q3. Its up 0.02, from 1.02 in 2017Q2. It increased, as 39 investors sold Incyte Corporation shares while 161 reduced holdings. 59 funds opened positions while 149 raised stakes. 188.97 million shares or 2.28% more from 184.77 million shares in 2017Q2 were reported. Ls Advsr Ltd Liability invested in 0.04% or 5,853 shares. Quantres Asset Mgmt owns 15,300 shares or 1.15% of their US portfolio. Nj State Employees Deferred Compensation Plan holds 0.28% or 13,000 shares. Creative Planning holds 0.01% of its portfolio in Incyte Corporation (NASDAQ:INCY) for 13,526 shares. Gamco Inc Et Al has invested 0% of its portfolio in Incyte Corporation (NASDAQ:INCY). 1832 Asset Mngmt Lp reported 15,047 shares or 0.01% of all its holdings. Moreover, Global X Mngmt Company has 0.04% invested in Incyte Corporation (NASDAQ:INCY) for 11,523 shares. Advent Cap Mngmt De stated it has 0.11% in Incyte Corporation (NASDAQ:INCY). 38,200 were accumulated by Zurcher Kantonalbank (Zurich Cantonalbank). Lau Associates Limited Liability Corporation has invested 1.4% in Incyte Corporation (NASDAQ:INCY). Moreover, Peak6 Investments Lp has 0.04% invested in Incyte Corporation (NASDAQ:INCY). Da Davidson & invested in 9,075 shares or 0.02% of the stock. Princeton stated it has 0.48% in Incyte Corporation (NASDAQ:INCY). 93,378 are owned by National Bank Of Montreal Can. Citadel Advisors Llc reported 0.04% stake.

Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics in oncology in the United States and internationally. The company has market cap of $19.85 billion. It offers JAKAFI for the treatment of myelofibrosis and polycythemia vera cancers. It currently has negative earnings. The companyÂ’s clinical stage products include ruxolitinib cream that is in Phase II clinical trial for the treatment of alopecia areata and atopic dermatitis; and baricitinib, which is in Phase III clinical trial for treatment of rheumatoid arthritis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>